Nanovibronix, inc. (NAOV)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Revenues

530

318

-

-

-

-

Revenues

-

-

239

229

147

203

Cost of revenues

249

158

88

88

49

93

Gross profit

281

160

151

141

98

110

Operating expenses:
Research and development

514

614

693

584

399

431

Selling and marketing

1,096

1,212

465

514

377

301

General and administrative

3,822

2,637

2,084

1,359

746

589

Total operating expenses

5,432

4,463

3,242

2,457

1,522

1,321

Loss from operations

-5,151

-4,303

-3,091

-2,316

-1,424

-1,211

Interest expense

15

-

-

-

-

-

Financial income (expense), net

-47

22

-

-

-

-

Change in fair value of derivative liabilities

102

-

-

-

-

-

Loss on extinguishment of derivative liability

-288

-

-

-

-

-

Warrant modification expense

412

-

-

-

-

-

Financial expense, net (Note 12)

-

-

1,836

398

1,432

1,387

Loss before taxes

-5,811

-4,281

-4,927

-2,714

-2,856

-2,598

Income tax benefit

-17

-127

38

117

28

49

Net loss

-5,794

-4,154

-4,965

-2,831

-2,884

-2,647

Deemed dividend related to extension of February 2015 warrants to Common stock in January 2017

-

-

841

-

-

-

Total loss attributable to holders of Common stock, Preferred C stock and Preferred D stock

-

-

-5,806

-

-

-

Total comprehensive loss attributable to holders of Common Stock

-

-

-

-2,831

-2,884

-2,647

Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock

-0.83

-0.64

-1.17

-0.62

-0.82

-17.08

Weighted average common shares outstanding: Basic and diluted

6,939

6,448

4,964

4,578

3,536

155